By Nancy Lapid

(Reuters) -U.S. researchers are beginning to identify clinical characteristics that distinguish “super responders” to GLP-1 weight-loss drugs like Wegovy and Zepbound from patients who lose only moderate amounts of weight at best, according to a report published online ahead of peer review.

The massive data analysis may eventually help personalize treatment decisions for the drugs already being used by millions of patients. Individual patients’ health status before starting treatment can also help guide drug selection, the analysis suggests.

“If I am a clinician seeing patients, I need to know what medicine will best benefit my patient,” said study leader Venky Soundararajan of Massachusetts-based data analysis company nference. “I also need to know… what benefits and wha

See Full Page